Rationale for Offer
The Medical Group (the “Group”) is well established and profitable with a track record dating back to 1996 and to 2009 as an incorporated entity in Cyprus. In recent years the Group has achieved very high growth rates with respect to the range of services offered, turnover and profits. However, due to strictly personal circumstances, the prime movers are not in a position to commit the time and effort required henceforth to maintain these high growth rates.
Therefore, an opportunity is presented to suitable investors to acquire a majority interest in the Group, capitalize on the solid groundwork already laid down and achieve extraordinary growth.
Desired Investors’ Profile
New investors will be expected to take full Management control and devote the time and energy needed to take the Group to the next level. Current prime movers will provide support and training, otherwise they are ready to take a “back-seat” as minority shareholders, unless of course an outright acquisition is agreed. In the case of an acquisition for anything less than 100%, investors will need to demonstrate their ability to effectively manage and grow the business, either by virtue of their track record/experience or their existing business network, preferably both.
The Group offers a wide range of mainstream medical and alternative medical treatments, as well as anti-ageing/ rejuvenation therapies. Its client base is to a large extent based on incoming medical tourism, however international licensing and joint ventures have started with huge further prospects to achieve rapid expansion.
The Group is uniquely positioned within the domestic (Cyprus) market, as it enjoys a virtual monopoly for certain highly specialized medical treatments, but also in the international market, as it’s the exclusive licensee outside the Americas of cutting-edge treatments developed by a USA-based biotechnology firm.
The Group operates two medical facilities in Cyprus, both are leasehold.
The consistently high growth rates of the Group, together with the lucrative prospects of the new Stem Cell line of business, present considerable challenges in arriving at a fair value. Shareholders are reasonable in their expectations, aiming to achieve a valuation based on the average of actual 2019 & 2021 results and well documented 2022 projections. Audited EBITDA was €---.--- in 2019 and is expected to exceed €1,7 Million in 2022 after international travel limitations are lifted.
A valuation of in the range of €8 Million for 100% of the Group is expected, with suitable adjustments for smaller percentages. Deal terms, such as timing of payments, will also impact the final price-tag.
MINIMUM INITIAL INVESTMENT FOR A MINORITY STAKE TO BEGIN WITH, IS EURO 1 MILLION
A detailed Offering Memorandum is available for suitably qualified investors, subject to signing a Confidentiality Agreement.